The use of lipid formulations of amphotericin B for systemic fungal infections

Leukemia

Volumn 10, Issue 10, 1996, Pages 1570-1575

  Leenders, A C A P ^a   De Marie, S ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Amphotericin B; Animal model; Antifungals; Lipid based formulation; Liposomal formulation; Therapeutic index

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; DRUG CARRIER; FLUCONAZOLE; FLUCYTOSINE; INTRALIPID; LIPID; LIPOSOME;

ANAPHYLAXIS; ANIMAL MODEL; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDIASIS; CHILL; CLINICAL TRIAL; COCCIDIOIDOMYCOSIS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG STRUCTURE; FUNGAL MENINGITIS; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG ASPERGILLOSIS; MYCOSIS; NAUSEA; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RIGOR; SYSTEMIC DISEASE;

EID: 0029786060     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Perfect JR, Lindsay MH, Drew RH. Adverse drug reactions to systemic antifungals; prevention and management. Drug Safety 1992; 7: 323-363.
2. Janknegt R, De Marie S, Bakker-Woudenberg IAJM, Crommelin DJA. Liposomal and lipid formulations of amphotericin B: clinical pharmacokinetics. Clin Pharmacokinet 1992; 23: 279-291.
3. Gregoriadis G. Fate of injected liposomes: observations on entrapped solute retention, vesicle clearance and tissue distribution in vivo. In: Gregoriadis G (ed). Liposomes as Drug Carriers; Recent Trends and Progress. John Wiley and Sons: Chichester, 1988, pp. 3-18.
4. Juliano RL, Grant CW, Barber KR, Kalp MA. Mechanism of the selective toxicity of amphotericin B incorporated into liposomes. Mol Pharmacol 1987; 31: 1-11.
5. Wasan KM, Rosenblum MG, Cheung L, Lopez-Berestein G. Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B. Antimicrob Agents Chemother 1993; 247: 246-250.
6. Lopez-Berestein G, Mehta R, Hopfer RL, Mills K, Kasi L, Mehta K et al. Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B. J Infect Dis 1983; 147: 939-945.
7. Walsh TJ, Garrett K, Feuerstein E, Girton M, Allende M, Bacher J, Francesconi A, Schaufele R, Pizzo PA. Therapeutic monitoring of experimental invasive pulmonary aspergillosis by ultrafast computerized tomography, a novel, noninvasive method for measuring responses to antifungal therapy. Antimicrob Agents Chemother 1995; 39: 1065-1069.
8. Allende MC, Lee JW, Francis P, Dollenberg H, Berenguer J, Lyman CA, Pizzo PA, Walsh TJ. Dose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosis. Antimicrob Agents Chemother 1994; 38: 518-522.
9. Hostetler JS, Clemons KV, Hanson LH, Stevens DA. Efficacy and safety of amphotericin B colloidal dispersion compared with those of amphotericin B deoxycholate suspension for treatment of disseminated murine cryptococcosis. Antimicrob Agents Chemother 1992; 36: 2656-2660.
10. Clemons KV, Stevens DA. Comparative efficacy of amphotericin B colloidal dispersion and amphotericin B deoxycholate suspension in treatment of murine coccidioidomycosis. Antimicrob Agents Chemother 1991; 35: 1829-1833.
11. Mitsutake K, Kohno S, Miyazaki Y, Noda T, Miyazaki H, Miyazaki T, Kaku M, Koga H, Hara K. In vitro and in vivo antifungal activities of liposomal amphotericin B and amphotericin B lipid complex. Mycopathologia 1994; 128: 13-17.
12. Perfect JR, Wright KA. Amphotericin B lipid complex in the treatment of experimental cryptococcal meningitis and disseminated candidosis. J Antimicrob Chemother 1994; 33: 73-81.
13. Allendoerfer R, Yates RR, Sun SH, Graybill JR. Comparison of amphotericin B lipid complex with amphotericin B and SCH 39304 in the treatment of murine coccidioidal meningitis. J Med Vet Mycol 1992; 30: 377-384.
14. Clemons KV, Stevens DA. Efficacies of amphotericin B lipid complex (ABLC) and conventional amphotericin B against murine coccidioidomycosis. J Antimicrob Chemother 1992; 30: 353-363.
15. Clarck JM, Whitney RR, Olsen SJ, George RJ, Swerdel MR, Kunselman L, Bonner DP. Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob Agents Chemother 1991; 35: 615-621.
16. Clemons KV, Stevens DA, Comparative efficacies of amphotericin B lipid complex and amphotericin B deoxycholate suspension against murine blastomycosis. Antimicrob Agents Chemother 1991; 35: 2144-2146.
17. Leenders ACAP, Ten Kate KT, Bakker-Woudenberg IAJM, De Marie S. AmBisome reduces dissemination of infection in a rat-model for one-sided pulmonary aspergillosis. J Antimicrob Chemother 1996 (in press).
18. Albert MM, Stahl-Carroll TL, Luther MF, Graybill JR. Comparison of liposomal amphotericin B to amphotericin B for treatment of murine cryptococcal meningitis. J Mycol Med 1995; 5: 1-6.
19. Francis P, Lee JW, Hoffman A, Peter J, Prancesconi A, Bacher J, Shelhamer J, Pizzo PA, Walsh TJ. Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of D-mannitol and galactomannan as markers of infection and therapeutic response. J Infect Dis 1994; 169: 356-368.
20. Albert MM, Adams K, Luther MF, Sun SH, Graybill JR. Efficacy of AmBisome in murine coccidioidomycosis. J Med Vet Mycol 1994; 32: 467-471.
21. Karyotakis NC, Anaissie EJ. Efficacy of escalating doses of liposomal amphotericin B (AmBisome) against hematogenous Candida lusitaniae and Candida krusei infection in neutropenic mice. Antimicrob Agents Chemother 1994; 38: 2660-2662.
22. Pahls S, Schaffner A. Comparison of activity of free and liposomal amphotericin B in vitro and in a model of systemic and localized murine candidiasis. J Infect Dis 1994; 169: 1057-1061.
23. Van Etten EWM, Van den Heuvel-de Groot C, Bakker-Woudenberg IAJM. Efficacies of amphotericin B-deoxycholate (Fungizone), liposomal amphotericin B (AmBisome) and fluconazole in the treatment of systemic candidosis in immunocompetent and leukopenic mice. J Antimicrob Chemother 1993; 32: 723-739.
24. Clemons KV, Stevens DA. Therapeutic efficacy of a liposomal formulation of amphotericin B (AmBisome) against murine blastomycosis. J Antimicrob Chemother 1993; 32: 465-472.
25. Adler-Moore JP, Chiang SM, Satorius A, Guerra D, McAndrews B, McManus EJ, Proffitt RT. Treatment of murine candidosis and cryptococcosis with a unilamellar liposomal amphotericin B formulation. J Antimicrob Chemother 1991; 28 (Suppl. B): 63-71.
26. Allen SD, Sorensen KN, Nejdl MJ, Durrant C, Proffitt RT. Prophylactic efficacy of aerosolized liposomal (AmBisome) and non liposomal (Fungizone) amphotericin B in murine pulmonary aspergillosis. J Antimicrob Chemother 1994; 34: 1001-1013.
27. Lopez-Berestein G, Fainstein V, Hopfer RL, Mehta K, Sullivan MP, Keating M et al. Liposomal-amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. J Infect Dis 1985; 151: 704-710.
28. Lopez-Berestein G, Bodey GP, Fainstein V, Keating M, Frankel LS, Zeluff B et al. Treatment of systemic fungal infections with liposomal amphotericin B. Arch Intern Med 1989; 149: 2533-2536.
29. Levine SJ, Walsh TJ, Martinez A, Eichacker PQ, Lopez-Berestein G, Natanson C. Cardiopulmonary toxicity after liposomal amphotericin B infusion. Ann Intern Med 1991; 114: 664-666.
30. Sculier JP, Coune A, Meunier F, Brassine C, Laduron C, Hollaert C et al. Pilot study of amphotericin B entrapped in sonicated liposomes in cancer patients with fungal infections. Eur J Cancer Clin Oncol 1988; 24: 527-538.
31. Clark JM, Whitney RR, Olsen SJ, George RJ, Swerdel MR, Kunselman L et al. Amphotericin B lipid complex therapy of experimental infections in mice. Antimicrob Agents Chemother 1991; 35: 615-621.
32. Walsh TJ, Hiemenz JW, Seibel N, Anaissie EJ. Amphotericin B lipid complex in the treatment of 228 cases of invasive mycosis. In: Program and Abstracts of the Thirty-Fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, USA, 1994; Abstract M69: p 247. American Society for Microbiology, Washington DC.
33. Anaissie EJ, White M, Uzun O, Singer C, Bodey GP, Matzke D, Azarnia N, Lopez-Berestein G. Amphotericin B Lipid Complex (ABLC) versus amphotericin B for treatment of hematogenous and invasive candidiasis. In: Program and Abstracts of the Thirty-Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, USA, 1995; Abstract LM21: p 330. American Society for Microbiology, Washington DC.
34. Sharkey PK, Graybill JR, Johnson ES, Hausrath SG, Pollard RB, Kolokathis A, Mildvan D, Fan-Havard P, Eng RHK, Patterson TF, Pottage JC, Simberfoff MS, Wolf J, Meyer RD, Gupta R, Lee LW, Gordon DS. Amphotericin B lipid complex compared to amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996; 22: 315-321.
35. Fielding RM, Smith PC, Wang LH, Porter J, Guo LSS. Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rat. Antimicrob Agents Chemother 1991; 35: 1208-1211.
36. Sanders SW, Buchi KN, Goddard MS, Lang JK, Tolman KG. Single-dose pharmacokinetics and tolerance of a cholesteryl sulfate complex of amphotericin B administered to healthy volunteers. Antimicrob Agents Chemother 1991; 35: 1029-1034.
37. Herbrecht R. A review of the safety of amphotericin B colloidal dispersion ('Amphocil'). Abstract No. 0-8. Trends in invasive fungal infections 3. Brussels, Belgium, 7-9 September 1995.
38. Hostetler JS, Caldwell JW, Johnson RH, Munoz AD, Einstein HE, Larsen RA, Stevens DA. Coccidioidal infections treated with amphotericin B colloidal dispersion (Amphocil, ABCD). Abstract 628. Abstr 32nd Intersci Conf Antimicrob Agents Chemother 1992, Anaheim, CA, USA.
39. Stevens DA. Overview of amphotericin B colloidal dispersion (Amphocil). J Inf 1994; 28 (Suppl. 1): 45-49.
40. Ringdén O, Meunier F, Tollemar J, Ricci P, Tura S, Kuse E et al. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother 1991; 28 (Suppl. B): 73-81.
41. Meunier F, Prentice HG, Ringdén O. Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. J Antimicrob Chemother 1991; 28 (Suppl. B): 83-91.
42. Laing RBS, Milne LJR, Leen CLS, Malcolm GP, Steers AJW. Anaphylactic reactions to liposomal amphotericin. Lancet 1994; 344: 682-683.
43. Ringdén O, Andström E, Remberger M, Svahn B-M, Tollemar J. Allergic reactions and other rare side-effects of liposomal amphotericin. Lancet 1994; 344: 1156-1157.
44. Mills W, Chopra R, Linch DC, Goldstone AH. Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-center experience of 133 episodes in 116 patients. Br J Haematol 1994; 86: 754-760.
45. Coker RJ, Viviani M, Gazzard BG, Du Pont B, Phole HD, Murphy SM, Atouguia J et al. Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS. Aids 1993; 7: 829-835.
46. Larsen RA, Leal MAE, Chan LS. Fluconazole compared to amphotericin B plus flucytosine for cryptococcal meningitis in AIDS; a randomized trial. Ann Intern Med 1990; 113: 183-187.
47. Saag MS, Powderly WG, Cloud GA, Robinson P, Grieco MH, Sharkey PK, Thompson SE, Sugar AM, Tuazon CU, Fisher JF, Hyslop N, Jacobson JM, Hafner R, Dismukes WE, NIAID Mycoses Study Croup, AIDS Clinical Trial Croups. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. New Engl J Med 1992; 326: 83-89.
48. Hann IM, Stevens RF, Pinkerton CR, Dardyshire PJ, Gibson BES, Oakhill A, Eestermans GH. Safety and efficacy of two regimes of ambisome versus amphotericin B as empiric antifungal treatment in neutropenic paediatric patients. Abstract No. 25, 2nd International Symposium on Febrile Neutropenia, Brussels, 14-16 December 1995.
49. Prentice HG, Catovsky D, Aoun M, Kvaloy S, Jacobs S, Herbrecht R, Schey SA, Bell AJ, Ellegaard J, Fiedler E, Fauser AA. Ambisome versus amphotericin B in patients with fever unresponsive to antibiotic therapy for 96 hours, or with confirmed fungal mycosis. Abstract No. 35, 2nd International Symposium on Febrile Neutropenia, Brussels, 14-16 December 1995.
50. Chavanet PY, Garry I, Charlier N, Caillot D, Kisterman J-P, D'Athis M et al. Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis. Br Med J 1992; 305: 921-925.
51. Caillot D, Cassasnovas O, Solary E, Chavanet P, Bonnotte B, Reny G et al. Efficacy and tolerance of an amphotericin B lipid (Intralipid) emulsion on the treatment of candidaemia in neutropenic patients. J Antimicrob Chemother 1993; 31: 161-169.
52. Yoly V, Geoffray C, Reynes J, Goujard C, Mechali D, Yeni P. A pilot study of deoxycholate amphotericin B associated with Intralipi® in the treatment of cryptococcal meningitis in patients with AIDS. In: Program and Abstracts of the Thirty-Third Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, 1993; Abstract 814: p 268. American Society for Microbiology, Washington DC.
53. Trissel LA. Amphotericin B does not mix with fat emulsion. Am J Health Syst Pharm 1995; 52: 1463-1464.
54. De Marie S, Janknegt R, Bakker-Woudenberg IAJM. Clinical use of liposomal and lipid-complexed amphotericin B. J Antimicrob Chemother 1994; 33: 907-916.
55. Tollemar J, Höckerstedt K, Ericzon BG, Jalanko H, Ringdén O. Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. Transplantation 1995; 59: 45-50.